No black box warning on record for Milrinone Lactate In Dextrose

As of the latest FDA labeling reviewed, Milrinone Lactate In Dextrose (MILRINONE LACTATE IN DEXTROSE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Milrinone Lactate In Dextrose medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Whether given orally or by continuous or intermittent intravenous infusion, milrinone has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure. In a multicenter trial of 1088 patients with Class III and IV heart failure, long-term oral treatment with milrinone was associated with no improvement in symptoms and an increased r

No black box warning on record for Milrinone Lactate In Dextrose

Other warnings & precautions

WARNINGS Whether given orally or by continuous or intermittent intravenous infusion, milrinone has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure. In a multicenter trial of 1088 patients with Class III and IV heart failure, long-term oral treatment with milrinone was associated with no improvement in symptoms and an increased r

Milrinone Lactate In Dextrose Black Box Warning

No black box warning on record for Milrinone Lactate In Dextrose

Other warnings & precautions

Milrinone Lactate In Dextrose Black Box Warning

No black box warning on record for Milrinone Lactate In Dextrose

Other warnings & precautions